Amarin (Nasdaq: $AMRN) Stock Hub 2026: The Supreme Court Defeat, The Recordati Model And $314.6 Million Of Cash Against A $295.9 Million Market Value

01 What Amarin Is In August 2026

Amarin Corporation plc is an Irish-incorporated pharmaceutical company with United States operations in
Bridgewater, New Jersey, listed on Nasdaq under the ticker $AMRN. It owns one commercial product,
icosapent ethyl, sold as VASCEPA in the United States and much of the world and as VAZKEPA in Europe, and it
has no clinical pipeline behind it. Everything the company is worth today rests on how much of that single
molecule can still be sold, at what price, and through whose sales force.

The shape of the business changed in June 2025, when Amarin signed an exclusive long-term licence and supply
agreement with Recordati S.p.A. covering 59 countries focused on Europe. That agreement, together with a global
restructuring programme targeting $70 million of annual operating expense savings, converted Amarin from a company
that ran its own commercial infrastructure across Europe into one that sells through partners everywhere except the
United States. On July 29, 2026 the company described the twelve months since as the first anniversary of a
“fully partnered international commercial strategy”.

The second quarter of 2026, reported that day, gives the clearest picture of what the new shape produces.
Total net revenue was $42.2 million, down 42 per cent from $72.7 million a year earlier. Operating expenses were
$27.0 million, down 59 per cent. The net loss was $7.7 million, against $14.1 million. Cash and short-term
investments stood at $314.6 million at June 30, 2026, up from $302.6 million at December 31, 2025, and the company
stated it remained debt free. Chief Financial Officer Peter Fishman said Amarin had generated positive cash flow
for the third consecutive quarter.

Two facts frame everything that follows. The first is that the revenue decline is largely mechanical: the
year-ago quarter contained a $25.0 million upfront payment from Recordati that will not repeat, and European product
revenue now arrives as transfer prices and royalties from a partner rather than as end-market sales booked by Amarin.
The second is that on June 4, 2026 the Supreme Court of the United States decided Hikma Pharmaceuticals USA Inc.
v. Amarin Pharma, Inc. against Amarin, closing the legal route that had, for two years, been the main source of
speculative upside attached to the shares.

What is left is a company with more cash than its own stock-market value, no debt, a declining but real United
States franchise, a partner network covering close to 100 markets, a cost base roughly half what it was, and an
investment bank retained to explore what to do next.

02 Icosapent Ethyl And The REDUCE-IT Evidence Base

Icosapent ethyl is a purified form of eicosapentaenoic acid, one of the two long-chain omega-3 fatty acids found
in fish oil. It is not fish oil: the formulation is a single ethyl ester, manufactured to pharmaceutical standards and
prescribed at four grams a day, and it contains no docosahexaenoic acid, the other omega-3 that in earlier
cardiovascular trials was associated with a rise in low-density lipoprotein cholesterol.

VASCEPA was first approved by the United States Food and Drug Administration in July 2012 as an adjunct to diet to
reduce triglyceride levels in adult patients with severe hypertriglyceridemia, defined as triglycerides at or above
500 mg/dL. That indication, known inside the company as the MARINE indication after the trial that supported it, is
a small market and it never sold well on its own.

The second indication is the one that matters commercially and legally. REDUCE-IT was a cardiovascular outcomes
study conducted over seven years and completed in 2018, following 8,179 patients at more than 400 sites in eleven
countries, all of them already on statin therapy with low-density lipoprotein cholesterol controlled between 41 and
100 mg/dL and triglycerides between 135 and 499 mg/dL. The primary results were published in the
New England Journal of Medicine in November 2018 and the total-events analysis in the
Journal of the American College of Cardiology in March 2019. On the strength of that evidence the FDA
approved VASCEPA in December 2019 for reduction of cardiovascular risk in statin-treated patients with elevated
triglycerides and either established cardiovascular disease or diabetes with additional risk factors.

The current United States label carries both indications. The cardiovascular one is written as an adjunct to
maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularisation and
unstable angina requiring hospitalisation, in adults with triglycerides at or above 150 mg/dL. The safety section is
short and specific: an increased rate of atrial fibrillation or atrial flutter requiring hospitalisation, 3 per cent
against 2 per cent on placebo, and an increased rate of bleeding, 12 per cent against 10 per cent, with the excess
concentrated in patients on concomitant antithrombotic medication.

In Europe, marketing authorisation for VAZKEPA was granted by the European Medicines Agency in March 2021 and by
the United Kingdom regulator in April 2021, both for reduction of cardiovascular risk in high-risk patients. The
company states that VASCEPA has been prescribed more than thirty-one million times since launch.

The evidence base is still being worked. On August 24, 2026 Amarin listed five company-supported abstracts accepted
for the European Society of Cardiology Congress in Munich, covering treatment adherence and legacy effects,
sex differences in study discontinuation, coagulation biomarkers, lipoprotein(a) variability and the oxidation of
lipoprotein(a) by eicosapentaenoic acid. These are post-hoc and mechanistic analyses of a trial that finished eight
years ago, presented by academic collaborators. They shape how cardiologists read the drug; they do not create a new
indication or a new revenue line.

03 The Generic Shock And What Survived It

The patent that protected the cardiovascular indication was tested in the District of Nevada and lost. On
March 30, 2020, following a trial concluded in January of that year, the court ruled in favour of Dr. Reddy’s
Laboratories and Hikma Pharmaceuticals USA, declaring several of Amarin’s patents covering the MARINE indication
invalid. Amarin appealed as far as the Supreme Court and was unsuccessful.

Generic entry followed quickly. According to the company’s own filing, Hikma obtained FDA approval for the MARINE
indication in May 2020 and launched the one-gram size in November 2020 and the half-gram in March 2023. Dr. Reddy’s
was approved in August 2020 and launched in June 2021 and June 2023. Teva Pharmaceuticals USA was approved in
September 2020 and launched in January 2023 and September 2022. All three remain active in the market.

The commercial effect was severe and is a matter of public record. Vascepa product revenue peaked at
$607.0 million in 2020 and was $580.3 million in 2021. Total revenue for 2022 was $92.0 million. That is not a
decline, it is a collapse, and it happened because the generics were priced far below the brand and because pharmacy
benefit managers moved volume to them at speed. Amarin responded with a restructuring in 2022 that cut roughly
40 per cent of its workforce.

What survived is the franchise being valued today, and it survived in a specific shape. In the
second quarter of 2026 Amarin’s share of the United States icosapent ethyl market was 48 per cent, up from 43 per cent
in the second quarter of 2025, and branded VASCEPA prescriptions rose 14 per cent year on year. United States product
revenue in the quarter was $32.2 million, down 12 per cent from $36.5 million. Volume is rising and revenue is
falling, which is the arithmetic of a market where net price per prescription keeps going down.

For the full year 2026 the company expects United States volumes to remain consistent. It does not guide to a
return to growth in United States revenue, and the second-quarter release attributes the decline explicitly to
“continued generic competition in the IPE market and the resulting pressure on net pricing”.

The patent estate did not end with the case that was lost. The 2025 annual report states that Amarin has pending
patent applications worldwide relating to potential new uses of icosapent ethyl or other derivatives of EPA, and to
potential new formulations of them, and that patents maturing from those applications would expire between 2030 and
2043. The company attaches no programme, no timetable and no cost to them: its own risk factors state that it cannot
reasonably estimate the timing, completion dates or costs of developing any derivative, combination or
next-generation product candidate. A pending application is not a product, and none of this appears in any guidance
the company has given. It is, however, the one route by which the intellectual property position around icosapent
ethyl could change without a court.

04 June 4, 2026: The Supreme Court Closes The Skinny-Label Route

The generics were approved for the MARINE indication only. They carved the cardiovascular indication out of their
labels, a practice permitted under United States law and known as a skinny label, because that indication was still
under patent. In commercial reality, the great majority of icosapent ethyl prescriptions are written for
cardiovascular risk reduction, so a generic sold on the narrow label captures demand generated by the patented use.

Amarin sued Hikma for induced infringement, arguing that the combination of the skinny label and Hikma’s public
conduct amounted to actively encouraging doctors to prescribe the generic for the patented indication. The evidence
cited included descriptions of the product as a generic equivalent of VASCEPA and press releases that quoted market
sales figures largely attributable to the cardiovascular use.

The case ran for six years. The District Court dismissed the claim. On June 25, 2024 the Court of Appeals for the
Federal Circuit reversed, finding that Amarin’s allegations plausibly stated a claim of active inducement. Hikma’s
petition for rehearing en banc was denied on October 17, 2024. Hikma petitioned the Supreme Court on
February 14, 2025, certiorari was granted on January 16, 2026, and the District Court proceedings were stayed. Oral
argument was heard on April 29, 2026.

On June 4, 2026 the Supreme Court reversed the Federal Circuit and remanded the case, finding, in the words of
Amarin’s own quarterly report, that “the Company failed to state a claim for active inducement, and thus, cannot
withstand Hikma’s motion to dismiss”. The decision was unanimous and was written by Justice Jackson. The Court
held that routine generic marketing conduct, including a skinny label, standard therapeutic-equivalence language and
investor-facing press releases, does not by itself constitute active inducement under 35 U.S.C. section 271(b), and
that inducement requires affirmative steps rather than regulatory compliance, omissions or vague statements.

Two consequences follow. The narrow one is that the specific damages claim against Hikma is gone at the pleading
stage, and the case returns to the District Court in a posture where Amarin has lost. The wider one is that the
skinny-label route is now materially safer for the generic industry as a whole, which removes any expectation that
United States net pricing on icosapent ethyl improves through the courts.

The litigation still costs money. Amarin recorded litigation-related charges of $6.3 million in the second quarter
of 2026 and $9.4 million in the first half, booked within general and administrative expense. Those charges are the
single largest reason the company’s non-GAAP result and its reported result diverge as much as they do.

05 The United States Business: Share Up, Revenue Down

The United States is the only market where Amarin still sells directly, with its own commercial organisation, and
it produced $32.2 million of the $42.2 million of second-quarter revenue. The dynamics there are unusual, and they separate cleanly into three numbers.

Market share is rising. Amarin held 48 per cent of the United States icosapent ethyl market in the second quarter
of 2026 against 43 per cent a year earlier. Branded prescriptions rose 14 per cent year on year. That is a brand
taking share back from generic competitors five years after those competitors arrived, which is not the normal
pattern in a genericised molecule.

Revenue is falling anyway. United States product revenue was down 12 per cent in the quarter and 6 per cent in the
first half, to $67.9 million from $72.2 million. The gap between rising volume and falling revenue is net price, and
net price in this category is set by rebates negotiated with pharmacy benefit managers against a generic reference
that costs a fraction of the brand.

The company’s guidance for the rest of 2026 is that United States volumes remain consistent. Read together with
the pricing trend, that points to a United States line that continues to erode slowly rather than one that stabilises,
unless mix or contracting changes.

The structural question this raises is what the United States commercial organisation is for. It is the largest
remaining cost in the business, it defends a franchise whose revenue declines every quarter, and it is the one part
of the operation that was not handed to a partner in 2025. Every scenario for the company runs through what happens
to it.

06 The Recordati Agreement And The Fully Partnered Model

In June 2025 Amarin granted Recordati S.p.A. an exclusive licence, with the right to sublicense, to develop and
commercialise VASCEPA in 59 countries focused on Europe, on the basis of the REDUCE-IT evidence. Amarin supplies
finished product to Recordati at a price set in the agreement. Amarin received an upfront payment of $25.0 million,
fully recognised in 2025, and is eligible for sales-based milestone payments totalling up to $150.0 million, each
payable once, plus royalties on net sales in the territory.

The commercial base handed over was already built. VAZKEPA had reached national reimbursement and launch in Sweden
in March 2022, Finland in December 2022, England, Wales and Northern Ireland in October 2022, Spain and the Netherlands
in September 2023, Scotland in September 2023, Greece in June 2024, Portugal in September 2024, Italy in January 2025,
Slovenia in October 2025, Romania in May 2026 and Austria in January 2026, with Denmark available under individual
reimbursement since June 2022. Switzerland has been available under individual reimbursement since January 2023 on a
Swissmedic approval. In Greece, Romania and Slovenia the local distribution agreements, with Vianex, Magnapharm and
Salus respectively, were transitioned to Recordati.

At June 30, 2026 VAZKEPA was commercialised in eleven European countries, and VASCEPA or VAZKEPA was commercially
available in 22 countries worldwide. In-market demand for VAZKEPA in Europe rose 69 per cent in the second quarter of
2026 against the second quarter of 2025.

The reported European numbers look worse than the underlying activity, and the reason is accounting rather than
demand. European product revenue was $5.4 million in the quarter, down 17 per cent, because Amarin no longer books
end-market sales in those countries: it books the transfer price of product shipped to Recordati, plus royalties.
The company states that quarter-to-quarter European comparisons on a consistent partnered basis begin only in the
third quarter of 2026, which means the first genuinely readable European comparison arrives with the results for the
period ending September 30, 2026.

The strategic logic is straightforward. Recordati is an established cardiovascular specialist across Europe with
an existing field force, and it carries the cost of pricing and reimbursement negotiations country by country. Amarin
keeps a royalty and a supply margin without funding a European infrastructure. What Amarin gives up is control over
the pace of the launch and most of the economics if the product does succeed.

07 China, Canada, MENA And The Rest Of The Partner Network

Outside the United States and the Recordati territory, Amarin sells through a syndicate of regional partners. The
quarterly report lists them by dossier. Under the United States new drug application dossier sit HLS Therapeutics in
Canada, Biologix FZCo across the Middle East and North Africa, and Eddingpharm for the China Territory, which covers
mainland China, Hong Kong, Macau and Taiwan. Under the European Medicines Agency dossier sit Recordati for Europe,
CSL Seqirus for Australia and New Zealand, Lotus Pharmaceuticals for Southeast Asia and Neopharm for Israel. The
company describes the network as covering close to 100 markets.

China is the largest of the non-European out-licences and the oldest. The development, commercialisation and
supply agreement with Eddingpharm was signed in February 2015. The transaction price disclosed in the quarterly
report totals $40.081 million: a $15.0 million upfront fee in February 2015, $1.0 million on submission of the
clinical trial application for the MARINE indication in March 2016, $5.0 million on its approval in March 2017,
$3.0 million on submission of the application for the REDUCE-IT indication in October 2023, $15.0 million on its
approval in June 2024, and $1.081 million of regulatory development support. Beyond that, Amarin is entitled to tiered
double-digit royalties on net sales in the China Territory, escalating to the high teens, and to sales-based
milestones ranging from $5.0 million to $50.0 million each, for a total of up to $120.0 million.

Volume in China is growing from a small base. Amarin reported 90 per cent year-to-date growth in in-market volume
in China in the second quarter release. Across the whole partner network, in-market demand for VASCEPA and VAZKEPA
rose 59 per cent in the second quarter of 2026 against the same quarter of 2025.

Two more launches are described as approaching. The company states that Singapore and South Korea are progressing
toward anticipated near-term commercialisation, without naming a date. These are company-stated expectations rather
than confirmed regulatory or launch dates.

The reported rest-of-world line does not yet reflect any of this smoothly. Rest-of-world product revenue was
$1.4 million in the second quarter of 2026 against $3.5 million a year earlier, a 61 per cent fall, which Amarin
attributes to normal variability in partner purchasing patterns and shipment timing across multiple geographies. For
the first half the same line was $4.2 million against $3.5 million, up 19 per cent. A revenue line that swings from
plus 19 per cent to minus 61 per cent depending on the window chosen is a line driven by when containers ship, not by
how many patients take the drug.

08 Second Quarter 2026 In Numbers

Amarin reported the three months ended June 30, 2026 on July 29, 2026. The figures below are taken from that
release and from the quarterly report on Form 10-Q filed the same day.

The revenue split by geography, for the same quarter: United States $32.2 million, down 12 per cent; Europe
$5.4 million, down 17 per cent; rest of world $1.4 million, down 61 per cent; licensing and royalties $3.1 million,
down 88 per cent. For the first half of 2026, total net revenue was $87.3 million against $114.8 million, a fall of
24 per cent, and the net loss was $18.2 million against $29.8 million.

Three movements inside that table explain the rest. The 88 per cent fall in licensing and royalty revenue is
the $25.0 million Recordati upfront dropping out of the comparison; the underlying royalty stream from Recordati is
inside the $3.1 million and is small. The 22 per cent rise in cost of goods sold against a 16 per cent fall in
product revenue compressed gross margin from $50.4 million to $15.0 million, a gross margin rate falling from
69 per cent to 36 per cent of total revenue. And the operating loss narrowed anyway, to $12.0 million from
$16.0 million, because $39.3 million of operating expense came out.

Amarin also publishes a non-GAAP result that strips stock-based compensation, restructuring, litigation-related
charges and one-off transaction fees. On that basis the second quarter of 2026 was a profit of $0.8 million against a
profit of $18.0 million a year earlier, and the first half was a loss of $1.0 million against a profit of
$10.3 million. The non-GAAP figures are the company’s own presentation and exclude $6.3 million of litigation charges
in the quarter.

09 The Cost Base After The $70 Million Programme

The cost programme announced alongside the Recordati agreement targeted approximately $70 million of annual
operating expense savings. On July 29, 2026 the company stated the programme was complete.

The headline is that operating expenses fell $39.3 million, or 59 per cent, to $27.0 million. That comparison
flatters, because the year-ago quarter carried $22.8 million of restructuring charges that were themselves the cost
of the cuts. Excluding restructuring from both periods, operating expenses fell $16.6 million, or 38 per cent, and
that is the number Chief Executive Aaron Berg used on the call day. Both figures appear in the company’s own release
and both are correct; they answer different questions.

Where the money came out is unambiguous. Selling, general and administrative expense fell to $22.2 million from
$38.7 million in the quarter, and to $43.3 million from $75.2 million in the first half. Research and development was
broadly flat at $4.8 million in the quarter and $9.4 million in the half, which is what a company with no clinical
pipeline spends: within that half-year figure, $0.45 million went to maintaining REDUCE-IT data and supporting
presentations, $1.0 million to regulatory filing fees, $0.09 million to non-clinical research and $6.8 million to
internal staffing and overhead, for $8.4 million excluding non-cash items, with a further $1.1 million of
stock-based compensation on top.

Cost of goods sold is the line moving the wrong way, up 22 per cent in the quarter to $27.2 million and up
39 per cent in the half to $54.6 million, on higher product volumes recognised in the period. In a partnered model
where product ships to licensees at a contractual transfer price, cost of goods sold and revenue no longer move
together the way they did under direct sales, and gross margin percentage becomes a less stable number quarter to
quarter.

Non-cash stock-based compensation fell to $2.1 million in the quarter from $4.3 million, and to $4.4 million in
the half from $10.4 million. That halving is consistent with a much smaller headcount, and it also reduces the annual
share issuance that equity compensation would otherwise create.

10 A Balance Sheet Larger Than The Market Value

At June 30, 2026 Amarin held $143.6 million of cash and cash equivalents, $0.2 million of restricted cash and
$171.1 million of short-term investments. The company reports the operating total as $314.6 million, against
$302.6 million at December 31, 2025 and $298.7 million a year earlier. It states it remained debt free.

The rest of the balance sheet: accounts receivable net of $92.9 million, down from $126.8 million at the year end;
inventory of $164.1 million, down from $195.9 million; total current assets of $602.8 million; total assets of
$624.4 million. On the other side, accounts payable of $18.8 million, accrued expenses and other current liabilities
of $145.4 million, total current liabilities of $164.2 million, and total liabilities of $180.7 million, of which
$5.3 million is a long-term operating lease liability. Total stockholders’ equity was $443.6 million. Accumulated
deficit was $1.7255 billion, which is the accounting record of everything spent to get here.

Two ratios follow from those figures and both are unusual for a company of this size. Cash and short-term
investments of $314.6 million exceed the entire stock-market value of the company, which was $295.9 million at the
close of August 21, 2026. And book value per share of $443.6 million against 21.00 million American Depositary Shares
outstanding puts the shares at roughly two thirds of stated equity, a price-to-book ratio of 0.66 according to Finviz
Elite on August 24, 2026.

Neither ratio means the cash is free. Total liabilities of $180.7 million sit against those assets, the business
still runs an operating loss, and a large part of stated equity is inventory and receivables rather than money in an
account. Cash net of all liabilities was $133.9 million at June 30, 2026. What the figures do establish is that the
company is not under financing pressure: there is no debt to refinance, no covenant to breach, and no maturity wall.

Cash generation, not just the cash balance, is the change the company points to. Amarin has now reported positive
cash flow in three consecutive quarters, and it expects cash at December 31, 2026 to be approximately 10 per cent
higher than at December 31, 2025. Applied to the $302.6 million year-end 2025 figure, that guidance implies roughly
$333 million at the end of 2026.

One asset does not appear on the balance sheet at all. At December 31, 2025 Amarin held combined United States and
non-United States net operating loss carryforwards of $1.0 billion, which do not expire, a total that fell by about
$8.9 million from the prior year after reconciliation to the filed 2024 foreign returns. Alongside them sit
$8.7 million of United States federal tax credit carryforwards and $3.3 million of state credits, which do expire,
between 2026 and 2044. Those losses carry no value in the accounts because a full valuation allowance sits against
them: the company does not currently expect to generate the taxable income needed to use them. For a purchaser that
could use them the calculation is a different one, which is why a loss pool of that size is part of what any buyer
would be pricing. Amarin’s own filing sets out the condition attached: using the Irish carryforwards depends on the
operations of its Ireland-based subsidiary remaining genuinely active in Ireland, and on the tax treaties between
Ireland and other countries not changing in a way that limits the offset.

11 The Inventory Question

Inventory of $164.1 million against quarterly product revenue of $39.1 million is the single strangest number on
the balance sheet. It represents roughly four times a quarter’s product sales in finished goods and materials,
carried at cost.

The direction of travel is the reassuring part. Inventory fell $19.5 million between March 31 and June 30, 2026,
and $31.8 million between December 31, 2025 and June 30, 2026. The Chief Financial Officer described the approach as
“a disciplined, data-driven approach to inventory management that optimizes working capital while protecting
product access”. Working inventory down converts a balance-sheet asset into cash without selling more product,
and it is part of why cash rose while the company was still loss-making.

The risk attached to it is equally plain. Icosapent ethyl capsules have a finite shelf life, and inventory built
for a larger commercial footprint than the company now operates carries the possibility of write-downs if it cannot
be sold or shipped to partners before it expires. No such charge has been taken in the periods reported here.

Quarter by quarter, the inventory line moves together with cash and has to be read alongside it. If cash
keeps rising while inventory keeps falling, a meaningful part of the cash improvement is the unwinding of working
capital, which is finite by definition. Amarin’s own guidance of roughly 10 per cent cash growth for 2026 does not
break out how much comes from operations and how much from working capital.

12 What The Company Has Guided To For 2026

The company set out its expectations for the full year 2026 in the second-quarter release. Stated plainly, they
are: continued growth in international markets; maintenance of VASCEPA’s United States market share; an improved
operating expense profile; and positive cash flow generation. On the specifics, United States volumes are expected to
remain consistent through the year, and cash at December 31, 2026 is expected to be approximately 10 per cent higher
than at December 31, 2025.

What that guidance does not contain is as informative as what it does. There is no revenue guidance, in dollars or
in growth rates. There is no earnings guidance, GAAP or non-GAAP. There is no date by which the company expects to
reach sustained profitability, and no milestone schedule for the Recordati or Eddingpharm sales-based payments. The
$150.0 million of Recordati milestones and the $120.0 million of Eddingpharm milestones are contractual maximums tied
to annual net sales thresholds that have not been disclosed, and neither the thresholds nor the timing are public.

The guidance is therefore best read as a commitment to the shape of the business rather than to its size: costs
stay down, cash goes up, share holds, international volume grows. Each of those four can be checked against the
third-quarter release without needing a forecast.

13 Barclays, The Strategic Process And The Board

The line in the second-quarter release that has the widest range of outcomes attached to it is a single clause in
the Chief Executive’s quote. Aaron Berg said the company continues to “work closely with Barclays, our exclusive
financial advisor, to explore additional potential pathways to further enhance shareholder value”.

A company with no debt, cash exceeding its market capitalisation, a completed cost programme, a single asset sold
through partners and an exclusive financial adviser retained is describing a strategic review in the language public
companies use for one. The phrase “additional potential pathways” is not defined in the release, and
Amarin has announced no transaction, no timetable, no process stages and no counterparties.

The pathways that a company in this position can pursue are known in general terms: a sale of the whole company;
a sale or further out-licensing of the United States commercial rights, which are the only rights not already
partnered; a return of capital to shareholders; a reverse merger or an acquisition that puts the cash to work in a
different asset; or continuing as an independent royalty-and-supply business. Nothing in the public record indicates
which of these, if any, is under consideration.

The board composition is relevant context here. Amarin’s directors, as put to the annual general meeting held in
Dublin on May 13, 2026, are Aaron Berg, Patrice Bonfiglio, Keith L. Horn, Odysseas Kostas, Louis Sterling III,
Diane E. Sullivan and Michael Torok. Several have direct professional links to Sarissa Capital Management, an
activist investor focused on healthcare. The 2026 proxy statement describes Patrice Bonfiglio as an adviser to
Sarissa Capital and a former president of the firm, and Odysseas Kostas, who chairs the board, as an adviser to
Sarissa where he was previously a partner, senior managing director and head of research. Boards constituted this way
generally exist to pursue a transaction or a return of capital rather than a long build.

That involvement is considerably older than the current board, and the filings date it precisely. Sarissa’s
quarterly position reports show no Amarin holding at March 31 or June 30, 2021, then 8,500,000 ordinary shares at
September 30, 2021 and 19,250,000 at December 31, 2021. On January 24, 2022 Sarissa Capital Management and
Alexander J. Denner filed a Schedule 13D reporting 24,000,000 ordinary shares, 6.06 per cent of the 395,825,887 then
outstanding, bought for an aggregate price of approximately $106.9 million. That is about $4.45 an ordinary share,
which at the ratio in force today works out at roughly $89 per American Depositary Share. The event date on the
filing is January 13, 2022, the day the holding crossed five per cent. The board changed a year later: Patrice
Bonfiglio, Keith L. Horn, Odysseas Kostas and Paul Cohen joined in February 2023, Oliver O’Connor in April 2023 and
Michael Torok in April 2025.

At June 30, 2026 Sarissa reported 1,673,395 American Depositary Shares, which is 33.5 million ordinary shares, or
roughly 7.9 per cent of the count on the cover of the latest quarterly report, and the position was unchanged across
the three preceding quarters. What the filings do not give is a blended cost for the shares added after the initial
block, so no single average entry price for the whole holding can be stated from the public record.

None of that is a prediction. The strategic review may produce nothing, may take longer than shareholders expect,
or may conclude that the current model is the best available. What can be said with certainty is that it is disclosed,
that it is ongoing as of July 29, 2026, and that any announcement arising from it would be the single largest event
for the shares in either direction.

14 Management, And The ADS Ratio Change That Rewrites The Chart

Aaron Berg is President and Chief Executive Officer. He is also a director, re-elected at the May 13, 2026 annual
general meeting. Peter Fishman is Chief Financial Officer. Both were quoted in the second-quarter release, Berg on the
commercial and strategic side and Fishman on the cost base, cash flow and inventory.

The current management team is the one that executed the pivot: the Recordati agreement in June 2025, the global
restructuring that followed, and the completion of the $70 million savings programme announced as done in July 2026.
Their predecessor, former chief executive Karim Mikhail, filed a complaint against the company in the Superior Court
of New Jersey on March 31, 2023 alleging constructive termination and seeking unspecified damages for breaches of his
employment agreement, the executive severance and change of control plan, and the implied covenant of good faith. The
case moved to the United States District Court for the District of New Jersey in April 2023 and is disclosed in the
company’s filings.

One corporate action from 2025 changes how every per-share number on this page must be read. Effective
April 11, 2025 Amarin adjusted the ratio of its American Depositary Shares to ordinary shares, from one ADS
representing one ordinary share to one ADS representing 20 ordinary shares. Holders of fractional ADSs received cash.
The change did not alter the number of ordinary shares outstanding and was not a reverse split of the underlying
equity, but for anyone holding or quoting the Nasdaq-listed security the effect on the quoted price and on per-ADS
figures is the same as a one-for-twenty consolidation.

The practical consequence is that historical $AMRN prices quoted before April 2025 are not comparable with prices
quoted after it unless they have been restated.

The share count itself starts from the figure the company states on the cover of its own quarterly report:
422,456,685 ordinary shares outstanding at July 24, 2026. Weighted average ordinary shares used for the earnings
calculation were 416.4 million basic in the second quarter of 2026 against 414.5 million a year earlier, an increase
of less than half a per cent; the gap between the two figures is treasury stock held by the company, which carried a
balance of $69.3 million at June 30, 2026. At twenty ordinary shares per ADS, 422.5 million ordinary shares
correspond to roughly 21.1 million ADS. Finviz Elite reported 21.00 million ADS outstanding on August 24, 2026 and
calculated the market capitalisation of $295.9 million from that count at the August 21 close. The difference between
the two is rounding and reference date, not new issuance.

15 Market Snapshot And Analyst Coverage

The market data below was read from Finviz Elite on August 24, 2026 and refers to the close of
August 21, 2026. Market readings change continuously and are the fastest-ageing figures on this page.

Three of those readings sit oddly together. Average daily volume of about 73,900 ADS
makes this a thin security in dollar terms, around $1 million of turnover a day, which means position sizes that are
trivial for an institution are not trivial for the order book. Short interest at 2.54 per cent of float is low, so
the price is not being set by a crowded short position. And a beta of 0.76 on a stock whose story is idiosyncratic
says the shares have been moving on their own news rather than with the market.

Analyst coverage is thin and hard to document to the standard used elsewhere on this page. The consensus price
target carried by Finviz Elite on August 24, 2026 was $12.50, which sits below the last close of $14.09. Individual
notes, the houses that issued them and their dates could not be confirmed against the issuing firms, so no table of
ratings is presented here. A consensus built on a handful of notes on a company with a market capitalisation under
$300 million is a weak signal in either direction, and a target below the market price is not in itself a
prediction of decline.

16 Retail Sentiment On Stocktwits

Stocktwits publishes a public sentiment stream for each ticker. The readings below were taken on
August 24, 2026 and describe self-reported tags posted by retail traders and non-professional investors. They are
not analyst research, they carry no accountability, and they are included because a thinly traded small
capitalisation is more exposed to retail flow than a large one.

The month behind the reading is more informative than the reading itself. The normalised community sentiment
score ran at 50 on July 21, climbed through the second-quarter release on July 29 to 68, then to 76 on July 31 and to
a peak of 91 on August 3. It then fell for two full weeks, through 43 on August 11 and 36 on August 13, to
19 on August 17, 15 on August 18 and a low of 12 on August 19, before recovering to 45 on August 21. No company
announcement was made between August 3 and August 21.

The two numbers in the box appear to contradict each other and do not. The share of sentiment-tagged messages
marked bullish was 93.75 per cent on August 24, while the normalised community score was 46, which the platform
labels neutral. The first counts the small number of posts on which somebody clicked a tag; the second is a
broader model of the stream. A high tagged-bullish percentage on a low absolute count measures the absence of
posted disagreement, not agreement.

Message volume on August 24 was labelled normal, at a score of 48, and the ticker ranked 47th on the platform’s
trending list. Watchers of the $AMRN stream numbered 30,399. That watcher count, on a stock with about $1 million of
daily turnover, is a legacy of the 2018 to 2021 period when this was one of the most heavily followed retail names in
biotechnology.

17 The Catalyst Map

Amarin has no PDUFA date, no advisory committee meeting and no pivotal readout pending. There is no clinical
pipeline behind icosapent ethyl. The catalyst map is therefore commercial, financial and corporate, and it looks
nothing like that of a development-stage biotechnology company.

The two dated items are the ESC Congress this week and the third-quarter results in the autumn. The ESC
presentations are academic analyses of a completed trial and change no forecast on their own. The third-quarter
results carry more weight than a routine quarter, because Amarin has stated that consistent European comparisons under
the partnered model begin with that period, and because it is the first checkpoint against all four elements of the
2026 guidance.

Everything else on the list has no date, and the largest of them, the strategic process, has no disclosed
timetable at all.

18 Risks And Red Flags

The revenue base is still declining. Total net revenue fell 42 per cent in the second quarter and
24 per cent in the first half. Part of that is the Recordati upfront dropping out of the comparison, but United
States product revenue, the largest line and the one not affected by the accounting change, fell 12 per cent in the
quarter and 6 per cent in the half on rising volumes. Net price per prescription is doing the damage.

The legal route is closed. The Supreme Court decision of June 4, 2026 removed the induced
infringement claim against Hikma at the pleading stage and made the skinny-label route safer for generic
manufacturers generally. Any thesis that assumed United States pricing would improve through litigation no longer has
a mechanism.

One product, no pipeline. Research and development spending of $9.4 million in the first half is
maintenance of an existing dossier, not the development of anything new. There is no second asset to absorb a further
deterioration in icosapent ethyl.

Inventory of $164.1 million. Four quarters of product sales sit on the balance sheet at cost.
Working it down releases cash, which is happening, but it also concentrates the risk of a write-down if product
cannot be shipped or sold before it expires.

Gross margin compression. Cost of goods sold rose 22 per cent in the quarter while product
revenue fell 16 per cent, taking gross margin from $50.4 million to $15.0 million. In a partner-supply model the
margin depends on contractual transfer prices, and Amarin has not disclosed them.

The partnered model transfers economics as well as cost. European in-market demand grew
69 per cent while European revenue booked by Amarin fell 17 per cent. Success in Europe now shows up as royalties and
supply margin, which is a fraction of end-market value, and Amarin no longer controls the pace.

Liquidity. Average daily volume of roughly 73,900 ADS, about $1 million a day at the last close,
makes both entry and exit slower than the market capitalisation would suggest.

Strategic uncertainty. A disclosed process with an exclusive financial adviser and no timetable
is an open-ended situation. It can end in a transaction, a return of capital, or nothing at all, and shareholders have
no information on which of those is more likely.

Concentration in one commercial organisation. The United States field force is the largest
remaining cost and defends the only market not handed to a partner. Any decision about it, in either direction,
changes the shape of the business materially.

19 Merlintrader Health Score

The Merlintrader Health Score is a one-to-five reading of how robust a company looks over the next twelve to
eighteen months, built on five weighted pillars. It is a description of financial and operational fragility, not a
view on the share price, and it is not a recommendation to buy, sell or hold anything.

Weighted, that gives a Merlintrader Health Score of 3.6 out of 5 as of August 24, 2026. The
profile is unusual: the balance-sheet pillars score at the top of the scale and the catalyst pillar near the bottom.
A company can be extremely hard to break and still have very little scheduled to happen to it, and that combination
is what the score is describing here.

20 Scenarios

The scenarios below are descriptions of how the situation could develop given what is on the public record. They
carry no probabilities, no price levels and no recommendation, and they are not forecasts.

The two cases are not symmetric in what would settle them. The constructive case depends on events that are not
scheduled: a transaction, a capital return, a milestone. The negative case depends on a trend that is already
measurable every quarter. The third-quarter results, expected in late October 2026 though not yet confirmed, are the
first point at which the partnered European model can be read on a consistent basis.

21 Bottom Line

Amarin in August 2026 is a company that has finished restructuring itself and has not yet decided what it is for.
The clinical story ended in 2018 with REDUCE-IT, the pricing story ended in 2020 with generic entry, and the legal
story ended on June 4, 2026 when the Supreme Court found unanimously that the induced infringement claim against
Hikma could not survive a motion to dismiss.

What remains is measurable. One product, sold directly in the United States and through partners in close to
100 markets. Total net revenue of $42.2 million in the second quarter of 2026, down 42 per cent, with United States
product revenue of $32.2 million falling 12 per cent on prescriptions rising 14 per cent. Operating expenses of
$27.0 million, cut by 59 per cent, from a $70 million savings programme the company has declared complete.
A net loss of $7.7 million. Cash and short-term investments of $314.6 million at June 30, 2026, no debt, equity of
$443.6 million, three consecutive quarters of positive cash flow, and a share count that has barely moved.

Set against a market capitalisation of $295.9 million at the August 21, 2026 close, those figures describe a
company valued at less than the cash on its balance sheet, which usually happens when the market expects the cash to
be consumed or the operating business to keep destroying value. Whether that expectation is correct depends on two
things that are not yet public: what the partnered international model produces once the comparisons become
consistent from the third quarter of 2026, and what comes out of the process being run with Barclays.

The next dated checkpoints are the European Society of Cardiology Congress in Munich from August 28 to 31, 2026,
where five company-supported analyses are scheduled, and the third-quarter results expected in late October 2026,
though that date has not been confirmed by the company.

Related Research On Merlintrader

• Biotech Stock Hubs — the full
  Merlintrader index of biotech and healthcare stock hubs, with the date each one was last verified.
• $AMRN turnaround check, January 2026 —
  earlier Merlintrader coverage, written before the Supreme Court decision of June 4, 2026 and before the second-quarter
  2026 results.
• $AMRN company history and analysis — the ten-year record
  from REDUCE-IT to generic entry, with the revenue figures for each year.
• Free Biotech Catalyst Calendar — PDUFA
  dates, advisory committee meetings and clinical readouts across the sector.